- E-cigarette use has negative effects on total and LDL cholesterol.
- E-cigarettes negatively impact the heart’s blood flow — possibly more chronically so than traditional cigarettes.
DALLAS — E-cigarette use takes a toll on heart health — a big concern given the high prevalence of e-cigarettes and perception of e-cigarettes as a healthier alternative to traditional cigarettes, according to new, preliminary research that will be presented at the American Heart Association’s Scientific Sessions 2019 — November 16- 18 in Philadelphia. The Association’s Scientific Sessions is an annual, premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.
Researchers who conducted two separate studies report they found e-cigarette smokers had more negative heart disease risk factors — namely, total and LDL cholesterol — and e-cigarettes decrease blood flow in the heart.
According to Rose Marie Robertson, M.D., FAHA, the American Heart Association’s deputy chief science and medical officer, “There is no long-term safety data on e-cigarettes. However, there are decades of data for the safety of other nicotine replacement therapies.”
The American Heart Association (AHA) recommends people quit smoking using smoking cessation aids that are FDA-approved and proven safe and effective. If people choose to use e-cigarettes as they work to stop smoking other tobacco products, they should also plan to subsequently stop using e-cigarettes, because of the lack of information on long-term safety and a growing body of data describing physiologic effects of the components of these devices and the chemical combinations used in them, Robertson said.
E-Cigarette Use is Associated with Altered Lipid Profiles in the CITU Study (Oral Presentation Mo3106)
In one study, researchers compared cholesterol, triglycerides and glucose levels in healthy adult nonsmokers, e-cigarette (e-cig) smokers, traditional cigarette (t-cig) smokers and dual smokers who use both traditional and e-cigarettes. Researchers evaluated healthy adults (ages 21-45) without existing cardiovascular disease and taking no daily medications in the Cardiovascular Injury due to Tobacco Use (CITU) Study. The study’s 476 participants included 94 non-smokers; 45 e-cig smokers; 52 e-cig and t-cig smokers; and 285 t-cig smokers. Analysis was adjusted for age, race, sex, and non-smokers, sole e-cig or t-cig use, or combination e-cig and t-cig use.
Among the study’s findings, total cholesterol and the bad cholesterol, LDL, was higher in sole e-cigarette users compared to nonsmokers.
“Although primary care providers and patients may think that the use of e-cigarettes by cigarette smokers makes heart health sense, our study shows e-cigarette use is also related to differences in cholesterol levels. The best option is to use FDA-approved methods to aid in
smoking cessation, along with behavioral counseling,” said study author Sana Majid, M.D., a postdoctoral fellow in vascular biology at the Boston University School of Medicine.
Co-authors of the study are Kathleen L. McGlasson, M.P.H.; Jessica L. Fetterman, Ph.D.; Rachel J. Keith, Ph.D., A.N.P.-C, C.T.T.S.; Robert M. Weisbrod, M.A.; Joseph N. Palmisano, M.P.H.; Rosa Breton-Romero, Ph.D.; Bihua Feng, M.D.; Comreen Vargees, M.S.; Aruni Bhatnagar, Ph.D.; Rose Marie Robertson, M.D., FAHA; and Naomi M. Hamburg, M.D., M.S., FACC. Author disclosures are in the abstract.
The American Heart Association Tobacco Center for Regulatory Science provided research materials for the study, and it was funded by The National Heart, Lung, and Blood Institute and the FDA Center for Tobacco Products.
Chronic E-Cigarette Users Demonstrate More Consistent Coronary Endothelial Dysfunction than Chronic Combustible Cigarettes (Oral Presentation Sa3199)
Smoking e-cigarettes is associated with coronary vascular dysfunction, and the effect might be worse than from smoking traditional cigarettes, according to another study. Researchers analyzed heart blood flow, a measure of coronary vascular function, of 19 young adult smokers (ages 24-32) immediately before and after smoking either e-cigarettes or traditional cigarettes. They examined coronary vascular function by a myocardial contrast echocardiography while participants were at rest and after performing a handgrip exercise to simulate physiologic stress.
“In smokers who use traditional cigarettes, blood flow increased modestly after traditional cigarette inhalation and then decreased with subsequent stress. However, in smokers who use e-cigs, blood flow decreased after both inhalation at rest and after handgrip stress,” said study author Florian Rader, M.D., M.S., medical director of the Human Physiology Laboratory and assistant director of the Non- Invasive Laboratory, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles. “These results indicate that e-cig use is associated with persistent coronary vascular dysfunction at rest, even in the absence of physiologic stress.”
“We were surprised by our observation of the heart’s blood flow being reduced at rest, even in the absence of stress, following inhalation from the e-cigarette,” added study co-author Susan Cheng, M.D., M.M.Sc., M.P.H., director of Public Health Research, also at Cedars-
Sinai Medical Center. “Providers counseling patients on the use of nicotine products will want to consider the possibility that e-cigs may confer as much and potentially even more harm to users and especially patients at risk for vascular disease.”
Co-authors are Mohamad Rashid, M.B., Ch.B.; Katherine Davoren, M.D.; Norma B. Moy, B.A.; Fida Nafeh, B.A.Sc., RDCS; Robert Elashoff, Ph.D.; Chulkyu Kim, B.A.; Andy Kim, A.B.; Elizabeth Kim, B.A.; and Michael D. Nelson, Ph.D. Author disclosures are in the abstract.
The California State Tobacco-related Disease Research Program High Impact Pilot Research Award funded the study.
“The American Heart Association believes more research is needed on e-cigarettes, and the Association is committed to fostering scientific discovery and dialogue on e-cigarettes through the American Heart Association Tobacco Center for Regulatory Science, our journals and meetings and our support of research grants,” Robertson said.
Statements and conclusions of study authors presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to
their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.
The American Heart Association’s Scientific Sessions is a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians. Scientific Sessions 2019 is November 16-18 at the Pennsylvania Convention Center in Philadelphia. More than 12,000 leading physicians, scientists, cardiologists and allied health care professionals from around the world convene at the Scientific Sessions to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to over 4,100 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in the Scientific Sessions conversation on social media via #AHA19.
The American Heart Association